BG-75202 features among several projects starting first-in-human trials.
ApexOnco Front Page
Recent articles
Inhibrx reveals three deaths in phase 1, but all predate screening protocols.
Posters and mini-orals include another VEGF bispecific.
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
Summit and Nuvalent have scored prized plenary spots.
Inclacumab fails, and osivelotor is on hold.
Shortly after ponsegromab, visugromab is to start phase 2/3.
